


## New/novel oral anticoagulants (NOACs) apixaban, dabigatran & rivaroxaban: Management of patients attending for endoscopy

**Apixaban** (Eliquis®), **dabigatran** (Pradaxa®) and **rivaroxaban** (Xarelto®) are new oral anticoagulants licensed for the following indications:

- Prevention of stroke in non-valvular atrial fibrillation (AF)
- Treatment of DVT/PE, and prevention of recurrent DVT/PE
- Primary VTE prophylaxis following total hip/knee replacement

Consider the risk of stopping anticoagulant therapy based on the indication.

Any patient prescribed a NOAC for an indication not listed on the guideline must be referred to a Consultant Gastroenterologist



\* Haemorrhoid banding - increased risk of delayed bleeding. If NOAC cannot be withheld for a prolonged duration (risk of bleeding up to 2 weeks after operation), consider conservative management only.

\*\* Before restarting NOAC always consider bleeding risk balanced against risk of thrombotic event.

- Todd H B, Kamath P S, McBane R D. New Anticoagulant and Antiplatelet Agents: A Primer for the Gastroenterologist Clinical Gastroenterology and Hepatology 2014; 12:187-195
- Apixaban (Eliquis®) Summary of Product Characteristics (Bristol-Myers Squibb-Pfizer) – accessed via <https://www.medicines.org.uk> on 3.4.15
- Dabigatran (Pradaxa®) Summary of Product Characteristics (Boehringer Ingelheim Ltd) – accessed via <https://www.medicines.org.uk> on 3.4.15
- Rivaroxaban (Xarelto®) Summary of Product Characteristics (Bayer PLC) – accessed via <https://www.medicines.org.uk> on 3.4.15
- Woodhouse C, et al. Frontline Gastroenterology 2013;4:213–218. doi:10.1136/figastro-2013-100325